Waltham-based Adagio Therapeutics announced on Monday that it has raised $336 million in new funding to rapidly advance its Covid-19 antibody treatment, which aims to treat and prevent the disease and all of its known variants.
Last week the Waltham biotech began recruitment for global clinical trial to test the drug’s efficacy as a treatment for high-risk individuals with mild or moderate Covid-19. The goal: to determine whether a single intramuscular dose could prevent hospitalizations and deaths.
“The COVID-19 pandemic continues to be a major health crisis worldwide, and even with emergency use authorizations for vaccines and antibody-based therapies, there remains a significant need for medications to treat and prevent COVID-19 infection,” said Tillman Gerngross, cofounder and chief executive officer of Adagio, in a press release.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect